Nivolumab
BMS
[]
 not suggesting it is practice-changing yet. however, the subset of pts who got to surgery &amp; achieved pcr in iiib remains- we need to understand who these pts are. even if a ph3 shows more modest benefit, the interpretation that some pts w iiib still benefit is likely to persist
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University